Female Infertility Tests: What They Measure and What Comes Next

When Does Delayed Pregnancy Need Medical Evaluation?

Infertility is medically defined as no pregnancy after twelve months of regular unprotected intercourse. For women over 35, this threshold drops to six months because ovarian reserve declines more rapidly after that age. A 2023 comprehensive review published in American Family Physician confirmed this framework and noted that delaying evaluation wastes rare time particularly for older women, since ovarian reserve cannot be recovered once lost.

Understanding the normal cycle helps set expectations. The egg matures in the ovary and is usually released around day fourteen of a twenty-eight-day cycle, then travels down the fallopian tube where fertilisation normally occurs. Sperm can survive in the female reproductive tract for three to five days, which means the most fertile window begins two to three days before ovulation. Regular intercourse every two to three days throughout the month is more effective than focusing only on the estimated ovulation day.

Even in healthy couples with no identifiable problem, the time from first attempt to conception ranges widely. Anxiety about delayed pregnancy is understandable, and the evaluation is a constructive step that either identifies a cause or provides reassurance. Coming to the evaluation knowing what to expect removes some of that anxiety.

Why Should the Male Partner Be Tested First or Simultaneously?

Social norms across much of the Arab world assign the responsibility for delayed pregnancy automatically to the woman. This is a medical error as well as a social one. A 2015 study published in Reproductive Biology and Endocrinology reviewing global infertility data found that male factor alone explains around 30 percent of cases, and that a shared male-female contribution accounts for a further proportion, making the male factor relevant in close to half of all infertility situations.

Semen analysis is straightforward and non-invasive. The man provides a sample at the laboratory and it is analysed for sperm count per millilitre, motility (the percentage moving), morphology (the percentage normally shaped) and the volume and composition of the ejaculate. All of these parameters affect the ability to fertilise an egg.

If the semen analysis is normal, attention shifts to the female factors. If it is abnormal, the man is referred to an andrologist, a specialist in male reproductive medicine, to look for treatable causes such as varicocele, hormonal imbalance or infection. Testing the male partner is a medical necessity, not a social accusation, and framing it this way in the clinic matters.

The Core Hormone Tests for Women

Blood tests drawn on day two or three of the menstrual cycle (the very start of the period) give a picture of ovarian reserve and hormonal balance. FSH, or follicle-stimulating hormone, is the main driver of egg development. A high FSH at the start of the cycle suggests the pituitary is working harder than usual to stimulate the ovaries, which signals reduced reserve. LH, or luteinising hormone, surges just before ovulation and is what home ovulation tests detect.

Estradiol (E2) on day two or three completes the interpretation of FSH. A high estradiol early in the cycle can suppress FSH and make it appear deceptively normal. For this reason FSH and estradiol are always read together, never in isolation. Prolactin elevation inhibits ovulation and causes cycle irregularities and sometimes nipple discharge outside of breastfeeding. Its most common cause is a small benign pituitary tumour called a prolactinoma, which is typically treated successfully with oral medication.

TSH, the thyroid-stimulating hormone, is essential in any fertility evaluation because both an underactive and an overactive thyroid disrupt ovulation and make conception harder. Many women do not know they have a thyroid problem until they investigate delayed pregnancy. Treating the thyroid disorder alone frequently restores regular ovulation.

What Is AMH and How Is It Interpreted?

AMH, or anti-Mullerian hormone, is secreted by the cells surrounding small follicles in the ovary. Its level reflects the size of the remaining egg pool more accurately than FSH. Its main practical advantage is that it can be measured on any day of the cycle without fasting, making it easier to schedule. A 2022 review in the Journal of Clinical Endocrinology and Metabolism concludes that AMH is currently the best available single marker for estimating ovarian reserve.

A significant study published in 2021 in Frontiers in Endocrinology by research teams based in the Gulf found that normal AMH values in Arabian Peninsula women may differ modestly from Western reference ranges and recommended that regional laboratories develop their own age-specific reference values. This means the number on your test result should be interpreted using the reference range of the specific laboratory that ran the test, not compared against a generic global table.

A 2025 mini-review published in Frontiers in Reproductive Health noted that women who are the offspring of consanguineous marriages in the Middle East may have a higher likelihood of reduced ovarian reserve compared with the general population. This is not a certainty for any individual, but it makes AMH testing particularly worthwhile in these cases, rather than something to defer.

Is Ovulation Actually Happening?

Confirming that ovulation occurs is a central step in the evaluation. The most direct method is follicular tracking by ultrasound (folliculometry), where the doctor monitors the growth and then disappearance of the dominant follicle containing the egg across several clinic visits. This provides direct confirmation of ovulation and its timing.

Progesterone on day twenty-one of the cycle (assuming a twenty-eight-day cycle) provides an indirect confirmation of ovulation. An elevated progesterone in the second half of the cycle confirms that ovulation occurred. Home ovulation tests that measure the LH surge are useful for timing intercourse but cannot confirm that the egg was actually released.

Absent or irregular ovulation is one of the most common causes of infertility. Polycystic ovary syndrome (PCOS) is the most frequent cause of ovulation dysfunction, affecting roughly 10 to 15 percent of women of reproductive age. A 2021 review in Gynecological Endocrinology describes the options for inducing ovulation in women with PCOS, ranging from lifestyle modification and oral medication to injectable hormones, and notes that most women with PCOS respond well to treatment.

Fallopian Tube Patency: Is the Route Open?

The fallopian tubes are the channel between the ovary and the uterus where fertilisation normally takes place. Blockage of one or both tubes by previous pelvic infection, endometriosis or surgical scarring prevents sperm from reaching the egg. Two main methods are used to assess tubal patency.

The first is a hysterosalpingogram (HSG), an X-ray procedure in which a contrast dye is injected into the uterus and its passage is imaged. It takes only a few minutes and can be uncomfortable, but it provides a clear picture of the uterine cavity and whether the tubes are open. Some evidence suggests the diagnostic dye passage itself slightly increases the probability of conception in the following months.

The second is laparoscopy, a surgical procedure under general anaesthesia that allows direct visualisation of the ovaries, tubes and uterus. It is used when endometriosis or intra-abdominal adhesions are suspected, and problems found can sometimes be treated in the same session. Laparoscopy is a more definitive diagnostic tool but carries the risks of any surgical procedure and is not a first-line investigation.

The Role of Endometriosis in Infertility

Endometriosis is a condition in which tissue similar to the uterine lining grows outside the uterus, commonly on the ovaries, tubes or within the pelvis. It causes often severe monthly pain and affects fertility through several mechanisms, including inflammation, adhesions and effects on egg quality. Diagnosis generally requires laparoscopy and cannot be excluded by blood tests or imaging alone.

Endometriosis affects roughly 5 to 10 percent of women of reproductive age overall, and this rises to 25 to 50 percent among women presenting with infertility, making it a significant cause to investigate. Treatment is surgical for more advanced disease and hormonal for milder forms. Many women with mild to moderate endometriosis conceive naturally or with minimal assistance after treatment.

A diagnosis of endometriosis does not mean conception is impossible. The degree of the disease and the individual's age and ovarian reserve together guide the treatment plan. Severe disease with tube blockage or significant adhesions requires specialist fertility care, whereas minimal disease with a good ovarian reserve may need only careful timing and monitoring.

What Happens After the Initial Tests?

After the initial tests, the doctor and couple have a picture that either identifies a cause or points toward further investigation. In roughly 10 to 20 percent of cases no specific cause is found through standard evaluation, a state called unexplained infertility. This does not mean everything is normal; it means the cause is not detectable with currently available tools, and empirical treatment is still possible.

Treatment options are matched to the cause, the woman's age and the duration of infertility. Oral ovulation induction, injectable hormones, intrauterine insemination (IUI) and in-vitro fertilisation (IVF) are available in varying combinations across Saudi Arabia, the UAE, Jordan, Egypt, Kuwait, Tunisia, Morocco and other Arab countries, though access and cost vary significantly between settings.

The psychological and social dimension is real and clinically significant. A 2019 paper published in the Journal of Assisted Reproduction and Genetics examining infertility from an Arabian sociocultural perspective highlighted that social pressure and stigma delay help-seeking in the region and affect how couples experience treatment. Psychological support for both partners is not a luxury but a documented component of better outcomes in infertility care.

Sources

• Phillips K, Olanrewaju RA, Omole F et al: Infertility: Evaluation and Management, American family physician, 2023
• Cedars MI: Evaluation of Female Fertility-AMH and Ovarian Reserve Testing, The Journal of clinical endocrinology and metabolism, 2022
• Melado L, Vitorino R, Coughlan C et al: Ethnic and Sociocultural Differences in Ovarian Reserve: Age-Specific Anti-Mullerian Hormone Values and Antral Follicle Count for Women of the Arabian Peninsula, Frontiers in endocrinology, 2021
• Bayoumi R, Riad J, Pillai S et al: Reduced ovarian reserve among female offspring of consanguineous marriages in the Middle East-a mini review, Frontiers in reproductive health, 2025
• Lawrenz B, Coughlan C, Melado L et al: Ethnical and sociocultural differences causing infertility are poorly understood-insights from the Arabian perspective, Journal of assisted reproduction and genetics, 2019
• Agarwal A, Mulgund A, Hamada A et al: A unique view on male infertility around the globe, Reproductive biology and endocrinology : RB&E, 2015
• Collee J, Mawet M, Tebache L et al: Polycystic ovarian syndrome and infertility: overview and insights of the putative treatments, Gynecological endocrinology, 2021